title: Blood rheology and 2,3-diphosphoglycerate levels after erythropoietin treatment.
abstract: Twenty-seven transfusion dependent patients with end-stage renal disease on long-term dialysis had blood cell counts, serum chemistries, blood pressure, and whole blood viscosity measured, as well as having transfusion requirements assessed. Three months after the institution of recombinant human erythropoietin (rHU-EPO) (75 u per kg per wk), there was an 88 percent fall in transfusion requirement. After four months, the hematocrit increased from 24 +/- 3.8 to 25.6 +/- 4.2 percent, mean corpuscular volume from 93 +/- 4.9 to 97 +/- 6.6 fl, 2-3-diphosphoglycerate (2,3-DPG) from 13.2 +/- 3.2 to 15.6 +/- 4.3 microM per g of Hb. Whole blood viscosity fell from 14.1 +/- 2.1 to 12.7 +/- 2.3 seconds, and ferritin levels fell from 3282 +/- 3889 to 2131 +/- 2441 ng per ml. In eight patients in whom the dose of rHU-EPO was further increased by up to 50 units per kg three times weekly for three months, the hematocrit rose further to 29.3 +/- 3.0 percent and the rise in hematocrit was accompanied by a further increase in 2,3-DPG to 17.9 +/- 2.8 microM per g of Hb (p < 0.03). There were no major side effects or vascular complications.
authors.affiliation: Department of Medicine, Brown University, Providence, RI 02908.
authors.forename: J P
authors.initials: JP
authors.lastname: Crowley
authors.forename: J A
authors.initials: JA
authors.lastname: Chazan
authors.forename: J B
authors.initials: JB
authors.lastname: Metzger
authors.forename: L
authors.initials: L
authors.lastname: Pono
authors.forename: C R
authors.initials: CR
authors.lastname: Valeri
mesh_terms: D019794:2,3-Diphosphoglycerate; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001809:Blood Viscosity; D004163:Diphosphoglyceric Acids / Q000097:blood*; D004909:Erythrocyte Indices; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005293:Ferritins / Q000097:blood; D006400:Hematocrit; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D006435:Renal Dialysis; D012212:Rheology
chemical_list: D004163:Diphosphoglyceric Acids; D011994:Recombinant Proteins; D004921:Erythropoietin; D019794:2,3-Diphosphoglycerate; D005293:Ferritins